Cancer Treatment Reviews

Papers
(The TQCC of Cancer Treatment Reviews is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review228
Editorial Board220
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)208
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty203
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives152
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis132
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials126
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas120
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer111
Systemic therapy for older patients with early breast cancer108
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer99
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis92
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer85
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group80
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in78
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?77
Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications75
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis75
Surgical tumor volume reduction in patients with brain metastases: A systematic review and meta-analysis72
De-escalation strategies with targeted therapies in non-small cell lung cancer68
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma68
Editorial Board66
Emerging antibody-based therapies for the treatment of acute myeloid leukemia65
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.62
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features60
If it’s a target, it’s a pan-cancer target: Tissue is not the issue60
Optimizing care in early phase cancer trials: The role of palliative care59
Uncertainties and controversies in axillary management of patients with breast cancer58
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches58
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis58
Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges54
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?53
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials53
Editorial Board50
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment49
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck48
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes47
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC46
Roadmap to cure multiple myeloma46
Editorial Board44
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations44
Extracellular vesicles and the “six Rs” in radiotherapy43
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review43
Managing strategies of chemotherapy and radiotherapy-induced oral mucositis42
Overview of BH3 mimetics in ovarian cancer42
The immunogram of inflammatory breast cancer41
Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis41
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design41
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada40
Deciphering primary acinic cell carcinoma of the Breast: Insights from a comprehensive case series and Systematic review40
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma40
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier40
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside39
Optimizing outcomes and personalizing care with targeted agents in advanced cholangiocarcinoma38
De-escalation of axillary irradiation for early breast cancer – Has the time come?38
Long-term surveillance recommendations for young adult cancer survivors37
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives36
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities36
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)36
Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis36
Immunocytokines in cancer treatment: A systematic review35
Editorial Board35
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features35
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies34
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer34
Bone complications of cancer treatment34
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer34
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review32
Agnostic drug development revisited32
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer31
Editorial Board31
Malignant ascites: Current therapy options and treatment prospects31
Acknowledgement to Reviewers 202131
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)31
Systematic review of the CUP trials characteristics and perspectives for next-generation studies31
Editorial Board30
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review30
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?29
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review29
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers28
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes28
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review28
Local control strategies for management of NSCLC with oligoprogressive disease27
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review27
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis27
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification27
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications27
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?26
Review: Targeting EZH2 in neuroblastoma26
Pharmacotherapy for leptomeningeal disease in breast cancer26
Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]26
Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic revie26
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges26
Strategies for improving detection of circulating tumor DNA using next generation sequencing25
Engineering strategies to optimise adoptive cell therapy in ovarian cancer25
Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis25
Patient-reported outcome measure to implement routine assessment of cancer survivors’ unmet needs: An overview of reviews and COSMIN analysis24
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project24
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives24
Evolving immunotherapeutic solutions for triple-negative breast carcinoma24
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS – GROUP). Part I23
PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence23
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer23
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond23
Editorial Board22
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications22
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis22
Editorial Board22
Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review21
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression21
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis21
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis21
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors20
Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases20
Editorial Board20
Editorial Board20
Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies20
Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature20
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment20
SELNET clinical practice guidelines for soft tissue sarcoma and GIST20
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives20
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review20
Editorial Board20
Considerations regarding a network meta-analysis of targeted therapies for BRAF-mutant unresectable or metastatic melanoma20
Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672]19
Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis19
From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia19
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments19
A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors19
Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy19
Multimodality treatment of primary cardiac angiosarcoma: A systematic literature review19
0.13650512695312